Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPLEEMENT-1: ribociclib + letrozole in HR-positive/HER2-negative advanced breast cancer
NL-OMON49682Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ribociclib and letrozole in breast cancer, sponsored by Novartis. Primary endpoint: Adverse events. Started Jan 2017; status: active, not recruiting.
02
Drugs
ribociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON49682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49682.